Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 208-220

  Dahia, Patricia L M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Hypoxia; Hypoxia inducible factor (HIF); Hypoxia inducible factor subunit; Microarray; Multiple endocrine neoplasia Type 2 (MEN 2); Mutation; Neurofibromatosis Type 1 (NF1); Oxidative stress; Oxidoreductase; Paraganglioma; Pathway intersection; Pheochromocytoma

Indexed keywords

SUCCINATE DEHYDROGENASE; VON HIPPEL LINDAU PROTEIN;

CONFERENCE PAPER; DOWN REGULATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC LINKAGE; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SIGNAL TRANSDUCTION;

EID: 33845510751     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.023     Document Type: Conference Paper

References (49)

1. MANGER, W.M. & R.W. GIFFORD. 2002. Pheochromocytoma. J. Clin. Hypertens. (Greenwich) 4: 62-72.
2. BRYANT, J. et al. 2003. Pheochromocytoma: the expanding genetic differential diagnosis. J. Natl. Cancer. Inst. 95: 1196-1204.
3. GIMENEZ-ROQUEPLO, A.P. et al. 2003. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63: 5615-5621.
4. NEUMANN, H.P. et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459-1466.
5. DAHIA, P.L.M. et al. 2005. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1: e8.
6. DAHIA, P.L.M. et al. 2005. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res. 65: 9651-9658.
7. SUBRAMANIAN, A. et al. 2005. From the cover: gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102: 15545-15550.
8. WYKOFF, C.C. et al. 2001. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found. Symp. 240: 212-225; discussion 225-231.
9. EISENHOFER, G. et al. 2004. Distinct gene expression profiles in norepinephrine and epinephrine producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr. Relat. Cancer 11: 897-911.
10. KAELIN, W.G. JR. 2003. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14: 2703-2711.
11. KAELIN, W.G. JR. 2002. How oxygen makes its presence felt. Genes Dev. 16: 1441-1445.
12. SEMENZA, G.L. 2004. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda). 19: 176-182.
13. SEMENZA, G.L. 2002. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8: S62-S67.
14. 2 sensing. Science 292: 464-468.
15. 2-regulated prolyl hydroxylation. Science 292: 468-472.
16. APPELHOFF, R.J. et al. 2004. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279: 38458-38465.
17. MAXWELL, P.H. & P.J. RATCLIFFE. 2002. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13: 29-37.
18. EPSTEIN, A.C. et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
19. SEMENZA, G.L. 2002. Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med. 41: 79-83.
20. SELAK, M.A. et al. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIFα prolyl hydroxylase. Cancer Cell 7: 77-85.
21. GIMENEZ-ROQUEPLO, A. P. et al. 2002. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J. Clin. Endocrinol. Metab. 87: 4771-4774.
22. GOTTLIEB, E. & I.P. TOMLINSON. 2005. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5: 857-866.
23. POLLARD, P.J. et al. 2005. Accumulation of Krebs cycle intermediates and overexpression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14: 2231-2239.
24. BRIERE, J.J. et al. 2005. Mitochondrial succinate is instrumental for HIF1α nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet. 14: 3263-3269.
25. ISAACS, J.S. et al. 2005. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8: 143-153.
26. TOMLINSON, I.P. et al. 2002. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30: 406-410.
27. GERALD, D. et al. 2004. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118: 781-794.
28. ISHII, N. et al. 1998. A mutation in succinate dehydrogenase cytochrome B causes oxidative stress and ageing in nematodes. Nature 394: 694-697.
29. ISHII, T. et al. 2005. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res. 65: 203-209.
30. GIMENEZ-ROQUEPLO, A.P. et al. 2001. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69: 1186-1197.
31. TOMITSUKA, E. et al. 2003. Direct evidence for expression of type II flavoprotein subunit in human complex II (succinate-ubiquinone reductase). Biochem. Biophys. Res. Commun. 311: 774-779.
32. AU, H.C. & I.E. SCHEFFLER. 1998. Promoter analysis of the human succinate dehydrogenase iron-protein gene - both nuclear respiratory factors NRF-1 and NRF-2 are required. Eur. J. Biochem. 251: 164-174.
33. GUSTAFSSON, M.V. et al. 2005. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell. 9: 617-628.
34. KOSHIJI, M. et al. 2005. HIF-1α induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell. 17: 793-803.
35. KOSHIJI, M. et al. 2004. HIF-1α induces cell cycle arrest by functionally counter-acting Myc. EMBO J. 23: 1949-1956.
36. WYKOFF, C.C. et al. 2004. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 90: 1235-1243.
37. MACK, F.A. et al. 2003. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3: 75-88.
38. KONDO, K. et al. 2003. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1: E83.
39. KIM, W. & W.G. KAELIN JR. 2003. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13: 55-60.
40. RAVAL, R.R. et al. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25: 5675-5686.
41. CLIFFORD, S.C. et al. 2001. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10: 1029-1038.
42. HOFFMAN, M.A. et al. 2001. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10: 1019-1027.
43. BISHOP, T. et al. 2004. Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol. 2: e289.
44. LEE, S. et al. 2005. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
45. EISENHOFER, G. et al. 2004. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer 11: 423-436.
46. DOUWES DEKKER, P.B. et al. 2003. SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology. J. Pathol. 201: 480-486.
47. BIRNER, P. et al. 2000. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60: 4693-4696.
48. AEBERSOLD, D.M. et al. 2001. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61: 2911-2916.
49. TEMES, E. et al. 2005. Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J. Biol. Chem. 280: 24238-24244.